Differential core pharmacotherapy in bipolar I versus bipolar II disorder and European versus American patients not in a syndromal episode. (January 2020)

• Record Type: Journal Article
• Authors: Dell'Osso, Bernardo; Cremaschi, Laura; Arici, Chiara; Altamura, A. Carlo; Hooshmand, Farnaz; Do, Dennis; Shah, Saloni; Gershon, Anda; Holsinger, Alex; Yeon Park, Dong; Miller, Shefali; Wang, Po W.; Ketter, Terence A.
• Is Part Of: International clinical psychopharmacology. Volume 35:Number 1(2020:Jan.)
• Publication Date: 2020-01
• Subjects: antidepressants -- antipsychotics -- bipolar I disorder -- bipolar II disorder -- mood stabilizers -- pharmacotherapy; Psychopharmacology -- Periodicals; Psychotropic drugs -- Periodicals; Psychopharmacology -- periodicals; Psychotropic Drugs -- periodicals; 615.7805
• DOI: 10.1097/YIC.0000000000000282
• Languages: English
• ISSNs: 0268-1315

Abstract

Abstract : Assess bipolar disorder subtype and treatment location effects on bipolar disorder core pharmacotherapy. Outpatients not in a syndromal episode referred to the University of Milan and Stanford University Bipolar Disorder Clinics were assessed with SCID for the fourth Edition of the Diagnostic and Statistical Manual of Mood Disorders, and the Systematic Treatment Enhancement Program for Bipolar Disorder Affective Disorders Evaluation, respectively. Prevalence and clinical correlates of antidepressant, antipsychotic, and mood stabilizer use, in aggregate and individually, were compared in bipolar I (BDI) versus II (BDII) patients in Milan/Stanford and in Milan versus Stanford patients, stratified by subtype. Milan/Stanford pooled BDI versus BDII patients significantly more often took antipsychotic (69.8 versus 44.8%), mood stabilizers (68.6 versus 57.7%), and valproate (40.1 versus 17.5%), and less often took antidepressants (23.1 versus 55.6%) and lamotrigine (9.9 versus 25.2%). Milan versus Stanford patients (stratified by bipolar disorder subtype) significantly more often took antipsychotic (BDI and BDII), antidepressants (BDII), and valproate (BDII), and less often took lamotrigine (BDI). Research regarding bipolar disorder core pharmacotherapy relationships with bipolar subtype and treatment location is warranted to enhance clinical management.